Compare ARMP & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARMP | ANIK |
|---|---|---|
| Founded | N/A | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.7M | 133.1M |
| IPO Year | N/A | 1993 |
| Metric | ARMP | ANIK |
|---|---|---|
| Price | $7.35 | $9.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $9.00 | ★ $16.00 |
| AVG Volume (30 Days) | 99.2K | ★ 162.7K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,054,000.00 | ★ $112,806,000.00 |
| Revenue This Year | $8.43 | N/A |
| Revenue Next Year | N/A | $4.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 30.55 |
| 52 Week Low | $0.90 | $7.87 |
| 52 Week High | $16.34 | $18.37 |
| Indicator | ARMP | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 65.33 | 53.34 |
| Support Level | $6.81 | $9.76 |
| Resistance Level | $7.40 | $10.17 |
| Average True Range (ATR) | 0.67 | 0.37 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 89.99 | 60.93 |
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.